[Efficacy evaluation of Shengmai Injection in treating coronary heart disease based on random walk model].
OBJECTIVE
To evaluate the clinical effects of Shengmai Injection in treating coronary heart disease (CHD) based on correct syndrome differentiation and incorrect syndrome differentiation.


METHODS
The patients' information was collected through a system of individual diagnosis and treatment of CHD. The score of main symptoms was calculated and recorded during the treatment. Patients were divided into two groups (incorrect syndrome and correct syndrome groups) on the basis of syndrome differentiation treatment or not. The clinical therapeutic effects of the two treatments were evaluated based on statistic theory combined with random walk method.


RESULTS
There were 273 patients in the correct syndrome group and 4 patients died (case-fatality rate was 1.47%). There were 297 patients in the incorrect syndrome group and 7 patients died (case-fatality rate was 2.36%). In the correct syndrome group, random fluctuation peak of comprehensive evaluation index, walk steps, positive growth rate of walk, ratio, random fluctuation power-law, increase rate and record times of comprehensive evaluation index were 1 472, 13 617, 0.108 1, 9.25, 0.674 2, 0.470 6 and 3 128 respectively, while in the incorrect syndrome group, 1 030, 14 588, 0.070 6, 14.16, 0.660 6, 0.312 8 and 3 293 respectively. The random fluctuation power-law in both groups exceeded 0.5.


CONCLUSIONS
There is a long-range correlation between the comprehensive evaluation index and therapeutic method as the CHD patients were treated with Shengmai Injection. The clinical therapeutic effects of Shengmai Injection under correct syndrome differentiation are better than the effects of Shengmai Injection under incorrect syndrome differentiation.
Gao
Zhu-Ye
ZY
Department of Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
Xu
Hao
H
Chen
Ke-Ji
KJ
Shi
Da-Zhuo
DZ
Li
Li-Zhi
LZ
Zhou
Xue-Zhong
XZ
D000368:Aged; D003327:Coronary Disease / Q000188:drug therapy*; D003937:Diagnosis, Differential; D004338:Drug Combinations; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008516:Medicine, Chinese Traditional / Q000379:methods*; D008875:Middle Aged; D008962:Models, Theoretical
D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; C009252:fructus schizandrae, radix ginseng, radix ophiopogonis drug combination